Cimeio Therapeutics AG

Using our cell-shielding technology and precisely paired immunotherapies, we aim to significantly improve the eligibility and outcomes of hematopoietic stem cell transplants and adoptive cell therapy. Our proprietary immunotherapies deplete diseased cells, while our cell-shielding technology protects healthy transplanted cells and allows them to engraft. Because the transplanted cells are shielded, the immunotherapy can continue to be safely administered post-transplant to boost engraftment or treat minimal residual disease.